This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Dr. Aileen Marty, Infectious Disease ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
Add Yahoo as a preferred source to see more of our stories on Google. The recommendation, made by the CDC's Advisory Committee on Immunization Practices, acknowledges the increased risk of severe ...
UPDATE: The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. In a joint statement ...
The Food and Drug Administration (FDA) announced Thursday the approval of both Pfizer’s and Moderna’s updated COVID-19 vaccines for the 2024-2025 respiratory viral season. The updated vaccines are ...
Moderna COVID-19 vaccines were associated with a threefold increased risk of chronic urticaria and nearly fourfold increased risk of other types of urticaria compared to expected rates.
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results